Immune checkpoint inhibitors (ICIs), targeting programmed-cell death 1 (PD-1) and programmed-cell death ligand 1 (PD-L1) have transformed the treatment landscape of advanced-stage NSCLC (aNSCLC) [4]. Here, PDCD1 is linked to non-small cell lung carcinoma.